Landscape Capital Management L.L.C. bought a new position in Heska Corp (NASDAQ:HSKA) in the fourth quarter, Holdings Channel reports. The fund bought 2,603 shares of the medical research company’s stock, valued at approximately $209,000.
A number of other large investors also recently bought and sold shares of HSKA. Royal Bank of Canada grew its position in Heska by 96.9% in the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after purchasing an additional 499 shares during the period. SG Americas Securities LLC bought a new stake in Heska in the 3rd quarter worth approximately $108,000. Quantitative Systematic Strategies LLC bought a new stake in Heska in the 4th quarter worth approximately $206,000. Municipal Employees Retirement System of Michigan grew its position in Heska by 58.9% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 2,400 shares of the medical research company’s stock worth $211,000 after purchasing an additional 890 shares during the period. Finally, Envestnet Asset Management Inc. grew its position in Heska by 46.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 2,438 shares of the medical research company’s stock worth $215,000 after purchasing an additional 776 shares during the period. 85.92% of the stock is owned by institutional investors and hedge funds.
Shares of Heska Corp (NASDAQ HSKA) opened at $78.42 on Wednesday. Heska Corp has a 1 year low of $56.59 and a 1 year high of $115.00. The stock has a market cap of $562.02, a price-to-earnings ratio of 36.99, a PEG ratio of 2.13 and a beta of 0.82.
HSKA has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of Heska from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Aegis reissued a “buy” rating on shares of Heska in a research report on Tuesday, December 19th. BidaskClub downgraded shares of Heska from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. B. Riley set a $93.00 price objective on shares of Heska and gave the company a “hold” rating in a research report on Monday, February 26th. Finally, Sidoti raised shares of Heska from a “neutral” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, February 5th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Heska has an average rating of “Hold” and an average price target of $104.08.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.